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IGF1 Promotes Resistance to Apoptosis in Melanoma
Cells through an Increased Expression of BCL2,
BCL-X(L), and Survivin
Caroline Hilmi1,2, Lionel Larribere1,2, Sandy Giuliano1,2, Karine Bille1,2, Jean-Paul Ortonne1,2,3,
Robert Ballotti1,2 and Corine Bertolotto1,2
IGF1 plays a key role in the development and growth of multiple tumors and in the prevention of apoptosis. In
melanoma cells, IGF1 has been shown to mediate resistance to anoikis-induced apoptosis. However, the effect
of IGF1 on other proapoptotic stimuli has never been reported. Further, the molecular mechanisms by which
IGF1 mediates its prosurvival properties in melanoma cells remain unknown. Here, we demonstrate that IGF1
impairs the onset of tumor necrosis factor–related apoptosis-inducing ligand and staurosporine-induced
apoptosis in melanoma cells expressing either wild-type or oncogenic B-Raf. Further, we show that IGF1 inhibits
mitochondrial damage that occurs during apoptosis, thereby indicating that IGF1 acts at the level of
mitochondria to mediate its antiapoptotic stimuli. Accordingly, IGF1 increases the mRNA levels and protein
expression of antiapoptotic members of the BCL2 family—BCL2 and BCL-X(L)—and that of the inhibitor of
apoptosis protein, survivin. Further, their specific silencing by small interfering RNA prevents the protective
effect of IGF1. These findings therefore delineate the molecular mechanisms by which IGF1 mediates its
prosurvival properties and provide a basis for clinical strategies designed to neutralize IGF1 or its target genes.
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INTRODUCTION
Apoptosis is a critical mechanism for preventing the
accumulation of cells with tumorigenic potential. Many
stimuli, including death receptor ligands of the tumor necrosis
factor (TNF) family (Fas-L, TNF-related apoptosis-inducing
ligand (TRAIL)), which function in immune surveillance
against tumors, have been shown to initiate apoptosis
(Cretney et al., 2002; Takeda et al., 2002). Briefly, binding
of these ligands to their specific receptors promotes the
activation of initiator caspases 8 and 10. The cascade of
apoptosis ensues with the activation of the executive caspases
3, 6, and 7, which cleave a number of vital proteins, including
the DNA repair enzyme poly(ADP-ribose) polymerase (PARP),
thereby leading to DNA fragmentation and apoptotic cell
death (Earnshaw et al., 1999). In several cell types, apoptosis
relies on the mitochondrial contribution to amplify the death
signal (Peter and Krammer, 1998). The mitochondrial network
triggers the release of cytochrome c from mitochondria and, in
association with apoptotic protease-activating factor-1,
induces the activation of caspase 9, which in turn contributes
to the stimulation of caspase 3 (Kroemer, 1997; Kroemer
et al., 1997). Interestingly, the BCL2 family of proteins is a
critical mitochondrial intracellular checkpoint. Indeed, the
ratio of antiapoptotic (BCL2, BCL-X(L), MCL1) to proapoptotic
(BIM, BAD, BAX, BAK) molecules in this family constitutes a
rheostat that sets the threshold of susceptibility to apoptosis.
Execution of the apoptotic program is also controlled by an
inhibitor of apoptosis proteins (IAP), which can selectively
bind and inhibit caspases 3, 7, and 9, thereby preventing cell
death in response to multiple stimuli.
The malignant transformation of melanocytes leads to
melanoma, a highly aggressive tumor, which can ultimately
result in a metastatic lesion, the deadly form of the disease.
Production of growth factors by melanoma cells them-
selves or by the tumor microenvironment is a critical event in
the acquisition of the malignant phenotype. These locally
produced growth factors allow a sustained cell proliferation
and protect melanoma against apoptosis induced by antic-
ancer drugs and death-receptor ligands of the TNF family,
which could explain its resistance to chemotherapeutic
treatment and escape from the immune response.
IGF1 is one of these growth factors that plays an important
role in the proliferation of a variety of cell types, in the
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development and growth of multiple tumors and in the
prevention of apoptosis (Grimberg, 2003). The biological
actions of IGF1 are mediated by the ligand-induced activa-
tion of the IGF1 receptor (IGF1R), a transmembrane tyrosine
kinase linked to the Ras–Raf-mitogen-activated protein kinase
and the phosphatidylinositol-3 kinase–protein kinase B/Akt
signal-transduction cascades. Cells lacking this receptor
cannot be transformed by any of a number of oncogenes, a
finding that proves that the presence of the IGF1R is
important for the development of a malignant phenotype
(Ciampolillo et al., 2005).
Further, IGF1R expression increases with tumor progres-
sion (Kanter-Lewensohn et al., 1998; Satyamoorthy et al.,
2001), and downregulation of IGF1R expression or activity
causes growth arrest and apoptosis (Kanter-Lewensohn et al.,
1998; Maloney et al., 2003) and increases sensitivity of
mouse melanoma cells to radiotherapy (Macaulay et al.,
2001).
These observations indicate that IGF1 and IGF1R play
important roles in melanoma survival and progression.
However, in melanomas, the molecular mechanisms
involved in the prosurvival effect of IGF1 have never been
reported.
In this report, we have studied—in melanoma cells—the
effects of IGF1 on apoptosis mediated by a physiologic
death ligand of the TNF receptor family, TRAIL, and by
the cytotoxic drug staurosporine. We show that IGF1
exposure impairs activation of caspases, cleavage of PARP,
loss of the mitochondrial membrane integrity, and accumula-
tion of cells in the sub-G1 phase induced by these apoptotic
stimuli. Further, we find that IGF1 promotes resistance to
apoptosis through upregulation of antiapoptotic members of
the BCL2 family—BCL2 and BCL-X(L)—and that of the IAP
survivin.
In conclusion, this study provides, to the best of our
knowledge, previously unreported information on the mecha-
nisms by which IGF1 mediates its antiapoptotic properties
and increases the aggressive behavior of melanoma cells and
provides new therapeutic opportunities for melanoma treatment.
RESULTS
IGF1 impairs the onset of TRAIL-induced apoptosis in MeWo
melanoma cells expressing wild-type B-Raf
We evaluated the prosurvival properties of IGF1 on apoptosis
mediated by TRAIL, which is a key mediator of immunologic
cell-mediated death.
First, the efficiency of IGF1 was determined on the
phosphorylation of extracellular signal-regulated kinase
(ERK) 1/2 and AKT, which correlates with their activation
state (Figure 1a). Detection of AKT and ERK2 ensured the
even loading of each lane.
We next performed FACS analysis using propidium iodide
staining of MeWo melanoma cells exposed to TRAIL, IGF1,
or both stimuli (Figure 1b). We observed that TRAIL promoted
an accumulation of MeWo cells in the sub-G1 phase (50%),
which was not observed for control or IGF1-exposed
cells. Additionally, TRAIL-induced sub-G1 accumulation of
cells was reduced upon IGF1 exposure (29%). These results
indicate that IGF1 is able to decrease TRAIL-induced death of
metastatic MeWo melanoma cells.
Apoptosis is characterized by activation of initiator and
effector caspases, which in turn process cellular substrates,
leading to cell death. Caspase activation can be followed by
the disappearance of the zymogenic form and the appearance
of active fragments migrating at a lower molecular weight in
western blot. In MeWo melanoma cells, TRAIL induced the
processing of caspases 3 and 9, which was impaired upon
IGF1 exposure, as shown by the lower amount of active
fragments detected when cells were exposed to TRAIL plus
IGF1 compared to TRAIL alone (Figure 2a). In contrast, IGF1
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Figure 1. IGF1 impairs the onset of TRAIL-induced death in WTB-Raf MeWo
metastatic melanoma cells. (a) Cell extracts from MeWo melanoma cells
exposed to IGF1 for 30minutes were analyzed by western blot with
antibodies to phospho-Ser473 AKT (pAKT), phospho-Tyr204/Thr202 p42/44
ERK (pERK1/2), and total AKT and ERK2. (b) MeWo melanoma cells were left
untreated or were exposed to IGF1, TRAIL (T), or IGF1 plus TRAIL and then
analyzed by flow cytometry for DNA content. The percentage of cells in
sub-G1 is indicated on the histogram.
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Figure 2. IGF1 prevents caspase activation in MeWo melanoma cells.
(a) Cell extracts from MeWo melanoma cells exposed to IGF1, TRAIL (T), or
both were submitted to western blot experiments with antibodies that
recognize caspase 8 (CASP8), caspase 10 (CASP10), caspase 9 (CASP9),
caspase 3 (CASP3), the cleaved form of PARP (PARPcl), or ERK2. (b) Protein
extracts were used to assay the activity of caspase 3 or 9 using the respective
synthetic substrates Ac-DEVD-AMC and Ac-LEHD-AMC. Substrate hydrolysis
measured by production of free AMC was determined at 460 nm and is
expressed as fluorescence arbitrary units.
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did not prevent TRAIL-mediated caspase 8 processing.
Noteworthy, caspase 10 was not processed upon TRAIL
treatment in MeWo melanoma cells. Finally, we show that
IGF1 exposure impaired the cleavage of PARP, the best-
known substrate of caspases. ERK2 ensured the even loading
of each lane. Detection by western blot of active fragments
does not necessarily imply that caspases have been activated.
It was therefore necessary to carry out a caspase activation
assay (Figure 2b). Hence, the direct determination of caspase
9 and 3 activities using synthetic chromogenic substrates
showed a decrease in caspase 9 and 3 activity when cells
were incubated with TRAIL plus IGF1 compared to TRAIL
alone.
Altogether, we demonstrate that IGF1 protects MeWo
melanoma cells from TRAIL-induced apoptosis and that IGF1
mediates its antiapoptotic effects downstream of caspase 8.
IGF1 prevents TRAIL-induced apoptosis in A375 melanoma
cells expressing V600EB-Raf
Next, we investigated whether IGF1 could also show
antiapoptotic properties in metastatic melanoma cell
lines, such as the A375 cells, which harbor the oncogenic
V600EB-Raf mutation (Eskandarpour et al., 2005).
In A375 melanoma cells, IGF1 induced the phosphoryla-
tion of AKT but not that of ERK1/2, due to the V600EB-Raf
mutation that leads to a constitutively active ERK1/2 (Figure
3a). Detection of AKT and ERK2 ensured the even loading of
each lane. Further, FACS analysis showed that TRAIL induced
an accumulation of cells in the sub-G1 phase (about 47%),
which was inhibited upon IGF1 exposure (20%) (Figure 3b),
consistent with that observed in MeWo melanoma cells.
IGF1 also delayed caspase 3 and 9 activation as shown by
western blot experiments in which a lower amount of active
fragments was detected when cells were exposed to TRAIL
plus IGF1 compared to TRAIL treatment (Figure 4a). Interest-
ingly, IGF1 did not prevent the processing of caspase 8
mediated by TRAIL, and TRAIL did not promote the
processing of the zymogenic form of caspase 10 in A375
cells. Further, IGF1 impaired TRAIL-mediated cleavage of
PARP. Detection of ERK2 ensured the even loading of each
lane. Additionally, the direct measure of caspase activity using
synthetic substrates confirmed that IGF1 impaired TRAIL-
induced caspase 3 and 9 activation in A375 melanoma cells
(Figure 4b).
In conclusion, our results indicate that IGF1 promotes
resistance to apoptosis in metastatic melanoma cell lines with
the oncogenic V600EB-Raf mutation.
IGF1 prevents disruption of mitochondrial function
The fact that IGF1 blocked the activation of caspases 3 and 9
but not that of caspase 8 led us to hypothesize that IGF1
mediated its protective effects at the mitochondrial level.
Staurosporine activates the intrinsic apoptosis pathway,
which causes disruption of mitochondria, leading to the
activation of caspase 9 and then caspase 3 and finally to the
cleavage of PARP. Figure 5a shows, in both MeWo and A375
cells, that staurosporine induced the cleavage of PARP,
which was strongly decreased in the presence of IGF1,
thereby indicating that IGF1 acts at the mitochondrial level.
Accordingly, TRAIL promoted a decrease in the mitochon-
drial membrane potential (DCm) (29%), while in the
presence of IGF1 TRAIL-mediated loss of DCm was impaired
(11%) and matched that of IGF1 or the control condition (7%)
(Figure 5b). The decoupling agent trifluoromethoxy carbo-
nylcyanide phenylhydrazone, which promotes the almost
complete loss of the mitochondrial membrane potential
(94%), was used as a positive control.
Taken together, our results indicate that IGF1 impairs death
receptor- and cytotoxic drug-induced activation of caspases,
loss of mitochondrial membrane potential, and DNA frag-
mentation, thereby favoring melanoma cell survival.
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Figure 3. IGF1 impairs the onset of TRAIL-induced death in V600EB-Raf A375
melanoma cells. (a) Cell extracts from A375 melanoma cells exposed to
IGF1 for 30minutes were analyzed by western blot with antibodies to
phospho-Ser473 AKT (pAKT), phospho-Tyr204/Thr202 p42/44 ERK
(pERK1/2), and total ERK2. (b) A375 melanoma cells were left untreated or
were exposed to IGF1, TRAIL (T), or both and then analyzed by flow
cytometry for DNA content. The percentage of cells in sub-G1 is indicated on
the histogram.
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Figure 4. IGF1 inhibits caspase activation in A375 melanoma cells.
(a) Western blot experiments of A375 cell extracts, exposed to IGF1
(100 ngml1), TRAIL (50 ngml1), or IGF1 plus TRAIL (T) for 3 hours, were
performed with antibodies that recognize caspase 8 (CASP8), caspase 10
(CASP10), caspase 9 (CASP9), caspase 3 (CASP3), the cleaved form of PARP
(PARPcl), or ERK2. (b) Protein extracts were used to assay the activity of
caspase 3 or 9 using the respective synthetic substrates Ac-DEVD-AMC and
Ac-LEHD-AMC. Substrate hydrolysis measured by production of free AMC
was determined at 460 nm and is expressed as fluorescence arbitrary units.
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IGF1 mediates its antiapoptotic properties through upregulation
of BCL2, BCL-X(L), and survivin
Antiapoptotic members of the BCL2 family play a key role in
maintaining the integrity of the mitochondrial membrane.
Therefore, we investigated the effects of IGF1 on some
members of this family (MCL1, BCL2, and BCL-X(L)) that have
been involved in melanomagenesis. A time-course analysis
showed that IGF1 did not change the intracellular level of
MCL1, but stimulated the expression of BCL2 and BCL-X(L)
after 1 hour and 2 hours, respectively (Figure 6a).
Additionally, we focused our attention on the proteins of
the IAP family, which antagonize the activation of caspases
and therefore prevent apoptosis. IGF1 also promoted a time-
dependent increase in survivin expression that began to be
visible after 1 hour (Figure 6b). The IGF1 effect was
monitored by the detection of phospho-Ser473 AKT and
charge loading by detection of ERK2.
These results were confirmed by quantitative real-time
reverse transcription-PCR experiments, indicating that IGF1
exposure of A375 cells increased the mRNA levels of BCL2,
BCL-X(L), and survivin (Figure 6c). Finally, IGF1 was no
longer able to prevent the processing of PARP mediated by
TRAIL when survivin, BCL2, and BCL-X(L) were silenced with
specific small interfering RNA (siRNA) (Figure 6d).
These findings therefore indicate that, in melanoma cells,
IGF1 mediates its antiapoptotic properties at two levels: upstream
of mitochondria through upregulation of BCL2 and BCL-X(L) and
downstream of mitochondria through upregulation of survivin.
DISCUSSION
In this report, we show that IGF1 can suppress the extrinsic
and intrinsic apoptotic processes in metastatic melanoma
cells, in the presence of either wild-type B-Raf or the
oncogenic V600EB-Raf. Indeed, IGF1 impairs TRAIL- and
staurosporine-induced caspase 3 and 9 activation, loss of
the mitochondrial membrane potential, cleavage of PARP,
and DNA fragmentation. Further, we show that IGF1
mediates its antiapoptotic and prosurvival properties through
regulation of BCL2, BCL-X(L), and survivin.
It is noteworthy that IGF1 does not fully protect melanoma
cells from TRAIL-mediated apoptosis. However, it should
also be noted that the methods used to monitor apoptosis
concern a population of cells in which some would be fully
sensitive to IGF1 prosurvival effects and others would not.
This is consistent with the fact that, in a tumor, some cells
may display sensitivity to anticancer drugs while others may
be resistant. In line with this, IGF1, produced by fibroblasts in
the tumor microenvironment, could be one of the factors that
favor cell survival by preventing the effects of therapeutic
drugs, thereby leading to outgrowth of resistant cells and
limiting successful therapeutic treatment. Therefore, although
the antiapoptotic effect of IGF1 is not an ‘‘all-or-nothing’’
effect, it should not be neglected because it can have
a very important consequence on tumor progression and
recurrence.
At the time of these experiments, IGF1 did not show any
effect on cell proliferation. However, a longer time exposure
(36 hours) led to a stimulation of melanoma cell proliferation,
thereby indicating that IGF1 promotes melanoma cell
survival but can also favor their proliferation.
In humans, caspase 10 is closely related to caspase 8. They
both have been reported to be recruited and activated upon
activation of transmembrane receptors of the TNF receptor
family (Kischkel et al., 2001; Werner et al., 2002). In
melanoma cells, we show that caspase 10 is expressed but
is not proteolytically processed upon TRAIL exposure. This
observation is consistent with previous reports (Juo et al.,
1998; Feng et al., 2004). However, it is now established that
activation of initiator apoptotic caspases does not necessarily
require proteolytic processing to achieve the active form but
requires dimerization of inactive monomeric proforms
(Chang et al., 2003; Boatright et al., 2004). Therefore, we
cannot rule out that unprocessed caspase 10 is indeed
activated in melanoma cells in response to TRAIL.
The BCL2 family of intracellular proteins is the central
regulator of caspase activation acting at the mitochondria
level. This family is composed of opposing factions with anti-
and proapoptotic members that arbitrate the life-or-death
decision. Our results indicate that IGF1 does not change the
intracellular levels of BIM, BAX, or BAK or the phosphoryl-
ation of BAD. In contrast, we find that IGF1 increases the
expression of BCL2 and BCL-X(L) and that downregulation of
these two members inhibits the prosurvival effect of IGF1.
Consistently, upregulation of BCL2 and BCL-X(L) by IGF1 has
been reported in other cell types (Pugazhenthi et al., 1999;
Sekharam et al., 2003; Fischer-Posovszky et al., 2004).
Furthermore, downregulation of BCL2 or BCL-X(L) by siRNA
or antisense oligonucleotides sensitizes malignant melanoma
to apoptotic stimuli (Heere-Ress et al., 2002; Wacheck et al.,
2003; Chawla-Sarkar et al., 2004).
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Figure 5. IGF1 impairs TRAIL-induced mitochondrial damage. (a) MeWo
and A375 melanoma cells were left untreated or exposed to IGF1
(100 ngml1), staurosporine (St, 1mM), and IGF1 plus staurosporine for
4 hours. Cell lysates were subjected to western blot assays with antibodies to
cleaved PARP (PARPcl) and total ERK2. (b) Mitochondrial membrane
potential (DCm) was measured in A375 cells by the loss of MitoTracker Red
fluorescence. As a control of the staining, cells were incubated with the
decoupling agent trifluoromethoxy carbonylcyanide phenylhydrazone, which
induced the complete loss of the mitochondrial membrane potential. Data are
expressed as fluorescence arbitrary units.
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The IAP genes constitute a highly conserved family that
encodes proteins that directly bind and inhibit caspases.
Therefore, these proteins also play a critical role in deciding
cell fate. Overexpression of the IAPs in cancer cell lines and
primary tumor samples appears to be a frequent event and
has been shown to be protective. Survivin is a unique
member of the IAP family that regulates both cell survival and
cell cycle progression (Li and Ling, 2006). Survivin is highly
expressed in most cancers and is associated with chemother-
apy resistance, increased tumor recurrence, and shorter
patient survival, notably in individuals who have developed
melanoma (Takeuchi et al., 2005). Hence, inhibition of
survivin activity has been reported to promote apoptosis or to
sensitize melanoma cells to apoptotic stimuli (Chawla-Sarkar
et al., 2004).
In melanoma cells, IGF1 increases the expression of
survivin, and survivin silencing by siRNA impairs the
resistance to apoptosis driven by IGF1. This observation is
consistent with a previous report in which inhibition of IGF1
or IGF1R signaling induces apoptosis and a decrease in
survivin expression (Hopfner et al., 2006).
It is well documented that cancers with high levels of
BCL2, BCL-X(L), or survivin are resistant to a wide spectrum of
chemotherapeutic agents and radiation therapy. Therefore,
compounds that selectively abrogate the IGF1 signaling
pathway may be helpful in enhancing sensitivity of melanoma
cells to therapy.
These findings thus define an important role for IGF1 in
modulating tumor cell responsiveness to TRAIL and cytotoxic
drugs and delineate molecular mechanisms for the prosurvi-
val effect of IGF1. Importantly, they provide the basis for
therapeutic strategies designed to neutralize IGF1 or its target
genes.
MATERIALS AND METHODS
Antibodies
BCL2 antibodies were from Transduction Laboratories (Franklin
Lakes, NJ), BCL-X(L) and survivin antibodies were from Cell
Signaling Technology (Beverly, MA), and anti-MCL1 was from Santa
Cruz Biotechnology (Santa Cruz, CA). The other antibodies were
previously described (Larribere et al., 2004, 2005).
Cell cultures
Human A375 and MeWo melanoma cells were grown in DMEM
supplemented with 7% fetal calf serum and penicillin (100Uml1)/
streptomycin (50mgml1) (Invitrogen, San Diego, CA). Because
bovine serum usually provides a significant amount of IGF1, for all
experiments cells were serum starved before any treatment. IGF1
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Figure 6. IGF1 increases expression of BCL2, BCL-X(L), and survivin. (a, b) Time-course experiments of A375 cells exposed to IGF1 for the times indicated.
Protein extracts were subjected to western blot with antibodies to BCL2, BCL-X(L), MCL1, survivin, phospho-Ser473 AKT (pAKT), and total ERK2. (c) The relative
amount of BCL2, BCL-X(L), and survivin mRNA in A375 cells treated with IGF1 for 2 hours was determined by quantitative reverse transcription-PCR. All results
were normalized to SB34 values. The mRNA level in the control condition was normalized to 100. Results are the means±SD from three independent
experiments and are expressed as a percentage of that of control cells. (d) A375 cells were transfected with control siRNA (siC) or siRNA specific for survivin,
BCL2, or BCL-X(L) and then exposed to IGF1, TRAIL (T), or both. Cell lysates were analyzed by western blot for cleaved PARP, ERK2, survivin, BCL2, or
BCL-X(L).
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(Santa Cruz Biotechnology) was used at the concentration of
100 ngml1 and incubated with cells 30minutes before addition of
TRAIL 50 ngml1 (R&D systems) for 3 hours or staurosporine 1mM for
4 hours.
Flow cytometry analysis
Cells that were exposed to recombinant IGF1 and/or TRAIL were
detached in phosphate-buffered saline/EDTA 1mM and stained
with propidium iodide. Apoptotic cells containing a DNA content
o2N appeared in the sub-G1 region. Fluorescence was measured by
using the FL2 channels of a FACScan (Becton Dickinson, Cowley,
UK).
To assess mitochondrial membrane potential (DCm), cells were
exposed to MitoTracker Red 580nm in a concentration of 150 nM
(Molecular Probes, San Diego, CA) for 30minutes at 37 1C. Change
in dye fluorescence at 25 1C was analyzed by flow cytometry using
an excitation wavelength of 488 nm and emission wavelength of
580 nm.
Western blot assays
Proteins were extracted in radioimmunoprecipitation assay buffer
containing Tris–HCl (pH 7.5) 10mM, NaCl 5mM, sodium deoxy-
cholate 0.1%, Nonidet-P40 0.1%, SDS 0.2%, Na3VO4 1mM,
aprotinin 2mgml1, leupeptin 10mM, AEBSF (4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride) 1mM, and NaF 5mM.
Samples (30 mg) were separated by 10% SDS-PAGE, transferred onto
a polyvinylidene difluoride membrane (Millipore, Saint-Quentin-
en-Yvelines, France), exposed to the appropriate antibodies,
and visualized with the ECL system from Amersham (Arlington
Heights, IL).
Caspase activity
Proteins were extracted with a buffer containing HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) 50mM (pH 7.4),
NaCl 150mM, EDTA 20mM, Triton X-100 0.2%, dithiothreitol
5mM, leupeptin 10 mM, aprotinin 10 mgml1, and Na3VO4 1mM.
Samples (50 mg) were incubated with or without 0.2mM Ac-DEVD-
AMC (caspase 3) or Ac-LEHD-AMC (caspase 9) as substrate. To
assess specific caspase activity, hydrolysis was followed at different
times at 37 1C in the presence or absence of 5mM Ac-DEVD-CHO or
Ac-LEHD-CHO. Caspase activities were measured on a fluoroscan
by degradation of the synthetic substrate and production of
fluorescent AMC (7-amino-4-methylcoumarin) and were expressed
as arbitrary units.
mRNA preparation, real-time/quantitative PCR
mRNA isolation was performed according to the standard procedure.
Real-time reverse transcription-PCR was carried out with SYBR
Green I (Eurogentec, Angers, Belgium) and Multiscribe reverse
transcriptase (Applied Biosystems, Foster City, CA) and monitored
using an ABI Prism 7000 Sequence Detection System (Applied
Biosystems). Detection of the SB34 gene was used to normalize the
results. Primer sequences for each cDNA were designed using
Primer Express Software (Applied Biosystems) and are available upon
request.
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